NICE changes its mind on J&J’s Erleada in prostate cancerNICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed Share XNICE changes its mind on J&J’s Erleada in prostate cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-jjs-erleada-in-prostate-cancer/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
